Dear Colleagues


Increasing prevalence of metastasis diseases due to the growing of advanced years population and increasing pathogens within the atmosphere has been the key issue driving the Chronic hindering pulmonic malady market globally. Pharmaceutical firms are developing new bio-based medications together with bio-technology that guarantees large growth opportunities alongside property development for Lungs Disease market over consecutive decade. The world-wide Respiratory disease drug market may be a multi-billion dollar market that contains a history of many decades and has witnessed range of technological advancements and products development over the past few years. Approaching treatment methodologies like once-a-day combination merchandise and organism antibodies have created new opportunities for the market growth.

Conference Highlights:

- Lung Injury and Repair
- Paediatric lung diseases
- Lung Transplantation
- Tuberculosis
- Lung cancer
- Chronic Obstructive Pulmonary Disease
- Asthma and Allergy
- Pulmonary diseases-treatment and therapies
- Pathophysiology of COPD
- Respiratory Pharmacology & Care
- Lung Disease and Respiratory Health

https://respiratory.conferenceseries.com/
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:45</td>
<td>Registrations</td>
</tr>
<tr>
<td>09:45-10:00</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>10:00-10:45</td>
<td>Introduction&lt;br&gt;Trends in the use of outcome parameters for respiratory drug research&lt;br&gt;Robert Lins, SGS Clinical Research, Belgium</td>
</tr>
<tr>
<td>10:45-11:15</td>
<td>Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response.&lt;br&gt;Toidi Adekambi, Emory University School of Medicine, USA</td>
</tr>
<tr>
<td>11:35-12:05</td>
<td>Sarcoidosis&lt;br&gt;Qin Yimin, Mallinckrodt Pharmaceuticals, USA&lt;br&gt;Prevalence, risk factors and clinical correlates of chronic obstructive pulmonary disease in a rural setting in Tanzania</td>
</tr>
<tr>
<td>12:05-12:35</td>
<td>The role of SIRT1 in LPS-induced lung endothelial barrier dysfunction and lung injury in vivo&lt;br&gt;Weizhong Jin, Hangzhou First People’s Hospital-Nanjing Medical University, China</td>
</tr>
<tr>
<td>14:05-14:35</td>
<td>Healthcare Resource Utilization and Costs in Sarcoidosis Patients in a Commercially-Insured US Population&lt;br&gt;Michael Philbin, Mallinckrodt Pharmaceuticals, USA</td>
</tr>
<tr>
<td>14:35-15:05</td>
<td>Tuberculosis&lt;br&gt;Samuel Dinkneh, St Peter TB Specialized Hospital, Ethiopia&lt;br&gt;The value of EBUS in the diagnosis of bronchi Dieulafoy’s disease</td>
</tr>
<tr>
<td>15:05-15:35</td>
<td>Weizhong Jin, Hangzhou First People’s Hospital-Nanjing Medical University, China&lt;br&gt;The coexistence of cystic fibrosis and celiac disease&lt;br&gt;Sonia Shahid, Abbasi Shaheed Hospital, Karachi</td>
</tr>
<tr>
<td>16:30-17:30</td>
<td>Poster Presentations&lt;br&gt;P1 Predictive multiscale computational tool for simulation of lung absorption and pharmacokinetics and optimization of pulmonary drug delivery&lt;br&gt;Ravi Kannan, CFD Research Corp, USA&lt;br&gt;P2 Clinical and epidemiological profile of patients with chronic obstructive&lt;br&gt;Camillo Ruiz, Pontificial Bolivarian University, Colombia&lt;br&gt;P3 Design, synthesis and anti-tubercular potential of some new substituted 1,2,4-triazoles derived from isonicotinic acid hydrazides&lt;br&gt;Varsha Kashaw, Dr Harisingh Gour University, India&lt;br&gt;P4 The dangers of judicious amiodarone use: An unusual case of amiodarone toxicity&lt;br&gt;Kathryn Tapper, The Mayo Clinic, USA</td>
</tr>
</tbody>
</table>
Development of in-silico QSAR models of 1,2,4 oxadiazole derivatives as potential apoptosis inducer and anticancer agents

Sushil Kashaw, Wayne State University, USA

Depression and its frequency in patients with chronic obstructive pulmonary disease

Seyda Seemad Gilani, Clinical Psychologist, USA
About Paris

Paris is the capital of France and the country's largest city, also called as the city of lights. It is located on the river Seine. The population of the town is around a pair of two million and also the town features a multi-cultural tradition. The population of the city is around one-fifth of the France, which makes it the second largest metropolitan area in the European region. It is respected for its attractive city plan, architecture, museums, parks, elegant cuisine and abundant monuments. The climate in Paris is typically gentle over four season Extreme cold or heat is pretty rare, however rain isn't. There are light showers in Paris that can come and go fast all day long. In terms of economy France is ranked as the world's ninth largest and the European Union's second largest economy by purchasing power parity.

Paris Attractions

Mail us to know more!
For Abstract Submission Guidelines | For Reserving your slot | Proposals | Registration | Posters | Accommodations
No doubt you have lots of queries...
Why not get in touch..!
Drop us your query with details and we will call you right away

UK: Conference Series llc LTD
47 Churchfield Road
London, W3 6AY, Tel: +44-0-800-014-8923

https://respiratory.conferenceseries.com/